Charles Schwab Investment Management Inc. Sells 29,910 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Charles Schwab Investment Management Inc. reduced its position in USANA Health Sciences, Inc. (NYSE:USNA) by 14.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 179,022 shares of the company’s stock after selling 29,910 shares during the period. Charles Schwab Investment Management Inc.’s holdings in USANA Health Sciences were worth $6,789,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in USNA. KBC Group NV raised its holdings in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after acquiring an additional 519 shares during the last quarter. BOKF NA increased its stake in shares of USANA Health Sciences by 99.4% in the 2nd quarter. BOKF NA now owns 5,526 shares of the company’s stock worth $250,000 after purchasing an additional 2,755 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of USANA Health Sciences in the 3rd quarter worth $250,000. Price T Rowe Associates Inc. MD increased its stake in shares of USANA Health Sciences by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after purchasing an additional 494 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in shares of USANA Health Sciences by 4.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after purchasing an additional 322 shares in the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $37.70 on Thursday. The company has a fifty day moving average of $37.91 and a 200 day moving average of $40.88. USANA Health Sciences, Inc. has a fifty-two week low of $34.15 and a fifty-two week high of $54.81. The company has a market capitalization of $718.56 million, a P/E ratio of 13.32, a P/E/G ratio of 1.27 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same quarter last year, the firm earned $0.59 EPS. Analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Separately, DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday, October 23rd.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.